ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

BOULDER, Colo. (AP) _ Array BioPharma Inc. (ARRY) on Wednesday reported a loss of $29.6 million in its fiscal fourth quarter. The Boulder, Colorado-based company said it had a loss of 17 cents per ...

BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) announced today that the strategic alliance between Array and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

Clinical trial results from Array BioPharma's (Nasdaq: ARRY) wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical ...

Array BioPharma Inc. ARRY is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

* Array Biopharma Inc - ‍FDA informed array that based on their preliminary review of applications they have not identified any potential review issues * Array Biopharma Inc - ‍FDA set a target action ...

Over 1.2 million people in the US are living with melanoma, according to the National Cancer Institute‘s 2015 estimates, with the number of new cases steadily increasing. NCI estimates that 91,270 ...